Brokerages Set Roche Holding Ltd. (RHHBY) Target Price at $38.00
Shares of Roche Holding Ltd. (OTCMKTS:RHHBY) have received an average rating of “Hold” from the fifteen research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $38.00.
Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Roche from a “buy” rating to a “hold” rating in a report on Friday, January 5th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Roche in a report on Friday, December 29th. Citigroup downgraded Roche from a “buy” rating to a “neutral” rating in a report on Wednesday, October 18th. Piper Jaffray Companies reiterated a “buy” rating on shares of Roche in a report on Thursday, December 7th. Finally, Cowen reiterated a “buy” rating and set a $38.00 price target on shares of Roche in a report on Tuesday, September 19th.
Shares of Roche (OTCMKTS RHHBY) traded up $0.40 during trading on Tuesday, reaching $31.77. The company had a trading volume of 1,010,000 shares, compared to its average volume of 1,600,000. Roche has a 1-year low of $28.48 and a 1-year high of $36.82. The company has a market capitalization of $218,980.00, a P/E ratio of 22.06, a P/E/G ratio of 2.23 and a beta of 0.67. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.29 and a quick ratio of 0.92.
A number of large investors have recently made changes to their positions in RHHBY. Stonebridge Capital Advisors LLC bought a new position in Roche in the 3rd quarter valued at $221,000. New England Research & Management Inc. grew its stake in Roche by 11.6% in the 4th quarter. New England Research & Management Inc. now owns 26,257 shares of the company’s stock valued at $829,000 after purchasing an additional 2,730 shares during the period. Patten Group Inc. grew its stake in Roche by 12.2% in the 3rd quarter. Patten Group Inc. now owns 29,741 shares of the company’s stock valued at $847,000 after purchasing an additional 3,239 shares during the period. Chickasaw Capital Management LLC grew its stake in Roche by 33.3% in the 4th quarter. Chickasaw Capital Management LLC now owns 40,000 shares of the company’s stock valued at $1,265,000 after purchasing an additional 10,000 shares during the period. Finally, Sterling Capital Management LLC grew its stake in Roche by 4.6% in the 3rd quarter. Sterling Capital Management LLC now owns 58,107 shares of the company’s stock valued at $1,856,000 after purchasing an additional 2,535 shares during the period. Hedge funds and other institutional investors own 0.58% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.watchlistnews.com/brokerages-set-roche-holding-ltd-rhhby-target-price-at-38-00/1805064.html.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with Analyst Ratings Network's FREE daily email newsletter.